REG - Indivior PLC - Indivior Responds to Letter from Oaktree

IndiviorAnnouncement

08/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241108:nRSH4443La&default-theme=true

RNS Number : 4443L  Indivior PLC  08 November 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to
the Board of Indivior

Richmond, VA, November 8, 2024 - Indivior PLC (NASDAQ / LSE: INDV) the Board
of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes
the publication today of a letter from Oaktree Capital Management LP
("Oaktree") to the Board of Indivior.

The Board has engaged actively with Oaktree in recent weeks on these topics,
and remains open-minded about all proposals to enhance value creation. The
Board is focused on acting in the best interests of all shareholders as we
continue to execute on our strategy.

Indivior looks forward to further engagement with Oaktree and other
shareholders.

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD), overdose
and serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD. Headquartered in the United States in Richmond, VA, Indivior employs over
1,000 individuals globally and its portfolio of products is available in over
30 countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=05%7C02%7Cdavid.wisniewski%40Indivior.com%7C46151793371f4a5a147b08dced4812d0%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638646141028285945%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=vwwjBavEG8GHlzYIHaEEC6eKfaZlLZYEsM1w5sIS1B8%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=05%7C02%7Cdavid.wisniewski%40Indivior.com%7C46151793371f4a5a147b08dced4812d0%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638646141028306668%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=mWdLO9fvlp1vQv6%2F30I2DGhuwyieW3W262QTgrk4ZVQ%3D&reserved=0)
.

 

For Further Information

                                       VP, Investor Relations                      +1 804 402 7123

 Investor Enquiries   Jason Thompson   Indivior PLC                                jason.thompson@indivior.com
                      Tim Owens                                                    +1 804 263 3978

                                       Director, Investor Relations Indivior PLC   timothy.owens@indivior.com
 Media Enquiries      Jonathan Sibun   Teneo                                       +44 (0)20 7353 4200

                                       U.S. Media Inquiries                        +1 804 594 0836

                                                                                   Indiviormediacontacts@indivior.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RSPFSUEDWELSEFF